Madurai News

Diabetic Cardiomyopathy Pipeline: Emerging Therapies and Key pharma players involved by DelveInsight | Imbria Pharmaceuticals, Applied Therapeutics and Others.

 Breaking News
  • No posts were found

Diabetic Cardiomyopathy Pipeline: Emerging Therapies and Key pharma players involved by DelveInsight | Imbria Pharmaceuticals, Applied Therapeutics and Others.

April 20
16:47 2021
Diabetic Cardiomyopathy Pipeline: Emerging Therapies and Key pharma players involved by DelveInsight | Imbria Pharmaceuticals, Applied Therapeutics and Others.

Diabetic Cardiomyopathy Pipeline

Diabetic cardiomyopathy is a type of cardiovascular damage present in patients suffering from diabetes. It is characterized by myocardial dilatation and hypertrophy as well as a decrease in the systolic and diastolic functions of the left ventricle, and its presence is independent of the coexistence of ischemic heart disease or hypertension. Existence of this condition in a diabetic patient may have several therapeutic implications including: improving glycemic control, earlier use of calcium channel blockers (CCBs), ACE inhibitors and ARBs, exercise training, lipid-lowering therapy, and antioxidant and insulin-sensitizing drugs. Increasing evidence suggests that hyperglycemia is central to the pathogenesis of diabetic cardiomyopathy, which triggers a series of maladaptive events leading to cardiomyocyte apoptosis, collagen deposition, and cardiac fibrosis.

DelveInsight’s, Diabetic Cardiomyopathy Pipeline Insight, 2021,” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Diabetic Cardiomyopathy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Some of Diabetic cardiomyopathy Companies are:

  • Imbria Pharmaceuticals
  • Applied Therapeutics
  • And Many Others

 

Request for free Sample Page: https://www.delveinsight.com/sample-request/diabetic-cardiomyopathy-pipeline-insight

 

DelveInsight’s Diabetic cardiomyopathy report covers around 3+ products under different phases of clinical development like:

  • Late-stage products (Phase III)
  • Mid-stage products (Phase II and Phase I/II)
  • Early-stage products (Phase I/II and Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

 

Some of Diabetic cardiomyopathy Therapies are:

  • IMB-1018972
  • AT-001
  • And Many Others

 

Request for free Sample Page: https://www.delveinsight.com/sample-request/diabetic-cardiomyopathy-pipeline-insight

 

Current Diabetic cardiomyopathy Treatment Scenario and Diabetic cardiomyopathy Emerging Therapies:

  • How many companies are developing Diabetic Cardiomyopathy drugs?
  • How many Diabetic Cardiomyopathy drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Diabetic Cardiomyopathy?
  • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Diabetic Cardiomyopathy therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Diabetic Cardiomyopathy and their status?
  • What are the key designations that have been granted to the emerging drugs?

 

Request for free Sample Page: https://www.delveinsight.com/sample-request/diabetic-cardiomyopathy-pipeline-insight

 

Table of Contents:

Introduction

Executive Summary

Diabetic Cardiomyopathy: Overview

Pipeline Therapeutics

Therapeutic Assessment

Diabetic Cardiomyopathy – DelveInsight’s Analytical Perspective

In-depth Commercial Assessment

Diabetic Cardiomyopathy Collaboration Deals

Late Stage Products (Phase III)

AT-001: Applied Therapeutics

Drug profiles in the detailed report…..

Mid Stage Products (Phase II)

IMB-101897: Imbria Pharmaceuticals

Drug profiles in the detailed report…..

Pre-clinical and Discovery Stage Products

Drug name: Company name

Drug profiles in the detailed report…..

Inactive Products

Diabetic Cardiomyopathy Key Companies

Diabetic Cardiomyopathy Key Products

Diabetic Cardiomyopathy- Unmet Needs

Diabetic Cardiomyopathy- Market Drivers and Barriers

Diabetic Cardiomyopathy- Future Perspectives and Conclusion

Diabetic Cardiomyopathy Analyst Views

Diabetic Cardiomyopathy Key Companies

Appendix

Request for Detailed TOC: https://www.delveinsight.com/sample-request/diabetic-cardiomyopathy-pipeline-insight

 

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/report-store/diabetic-cardiomyopathy-pipeline-insight